CD40 and pancreatic ductal adenocarcinoma: Through reprograming M2-TAMs toward into M1-TAMs, humanized anti-CD40 antibodies could suppress progression of pancreatic cancer and provide a better prognosis, which was confirmed in mouse models and patients with pancreatic ductal adenocarcinoma (56).